Autoimmune & Inflammatory Clinical Trials in the UK (2026): Arthritis, IBD, Psoriasis and More
Autoimmune and inflammatory conditions affect millions in the UK, often causing years of pain before finding effective treatment. Clinical trials are transforming this landscape with targeted biologics, oral JAK inhibitors, and precision medicine approaches that match treatments to individual patients.
The Biologics and Biosimilars Landscape
Biologic drugs have revolutionised autoimmune disease treatment by targeting specific immune molecules rather than broadly suppressing the immune system. The next wave includes biosimilars — highly similar versions of established biologics that offer the same efficacy at lower cost. UK trials are testing biosimilars for several major autoimmune conditions, which could significantly expand access. Beyond biosimilars, trials are testing next-generation biologics with longer dosing intervals (monthly or quarterly instead of weekly) and dual-target biologics that block two inflammatory pathways simultaneously.
JAK Inhibitors: The Oral Revolution
JAK inhibitors represent a major advance: small molecule drugs taken orally that block inflammatory signalling pathways inside cells. Unlike biologics, which require injection or infusion, JAK inhibitors are tablets. UK trials are testing newer, more selective JAK inhibitors that aim to maintain efficacy while reducing the safety concerns seen with first-generation versions. Conditions being studied include rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and Crohn's disease.
Inflammatory Bowel Disease Breakthroughs
IBD research in the UK is particularly strong. Trials are testing stem cell therapy for fistulising Crohn's disease, microbiome transplantation for ulcerative colitis, and precision medicine approaches that match treatment to a patient's specific inflammatory profile. The UK IBD BioResource, a national database of patients willing to participate in research, enables rapid trial recruitment and has made the UK a global leader in IBD research.
Dermatology: Beyond Steroids
Psoriasis and eczema trials have moved well beyond steroid creams. Biologic drugs now offer clear or nearly clear skin for many patients with moderate to severe disease. Trials are testing next-generation topical treatments, oral small molecules, and biologic drugs with improved dosing schedules. The UK has world-leading dermatology research centres, particularly in London, Manchester, and Newcastle.